These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 18590491)

  • 1. [New therapeutic prospects in autosomal dominant polycystic kidney disease].
    Torra R
    Nefrologia; 2008; 28(3):257-62. PubMed ID: 18590491
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel?
    Walz G
    Nephrol Dial Transplant; 2006 Jul; 21(7):1752-7. PubMed ID: 16705023
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of vasopressin antagonists.
    Torres VE
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autosomal dominant polycystic kidney disease: pathophysiology and treatment.
    Rapoport J
    QJM; 2007 Jan; 100(1):1-9. PubMed ID: 17164322
    [No Abstract]   [Full Text] [Related]  

  • 5. [Adult dominant polycystic kidney disease: molecular mechanisms and new therapeutic possibilities].
    Rodríguez Pérez JC; Torres MJ
    Nefrologia; 2006; 26(6):651-2. PubMed ID: 17227240
    [No Abstract]   [Full Text] [Related]  

  • 6. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.
    Torres VE; Wang X; Qian Q; Somlo S; Harris PC; Gattone VH
    Nat Med; 2004 Apr; 10(4):363-4. PubMed ID: 14991049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic interventions for autosomal dominant polycystic kidney disease.
    Edelstein CL
    Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Autosomal dominant polycystic kidney disease: new insights and possible drugs].
    Meijer E; de Jong PE; van der Jagt EJ; Peters Do; Breuning MH; Gansevoort RT
    Ned Tijdschr Geneeskd; 2009 May; 153(20):968-74. PubMed ID: 19490717
    [No Abstract]   [Full Text] [Related]  

  • 9. [Polycystic kidney disease].
    Higashihara E
    Nihon Jinzo Gakkai Shi; 2007; Suppl 50th Ann():83-90. PubMed ID: 17899832
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.
    Meijer E; Gansevoort RT; de Jong PE; van der Wal AM; Leonhard WN; de Krey SR; van den Born J; Mulder GM; van Goor H; Struck J; de Heer E; Peters DJ
    Nephrol Dial Transplant; 2011 Aug; 26(8):2445-53. PubMed ID: 21393612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy for polycystic kidney disease? It's water, stupid!
    Grantham JJ
    J Am Soc Nephrol; 2008 Jan; 19(1):1-7. PubMed ID: 18032792
    [No Abstract]   [Full Text] [Related]  

  • 12. [Modern treatment of autosomal dominant polycystic kidney disease].
    Wołyniec W; Jankowska MM; Rutkowski B
    Pol Merkur Lekarski; 2008 Oct; 25(148):374-9. PubMed ID: 19145940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment?
    Hogan MC; Masyuk TV
    Clin J Am Soc Nephrol; 2023 Feb; 18(2):154-156. PubMed ID: 36754002
    [No Abstract]   [Full Text] [Related]  

  • 14. Ultrasonography-guided intracystic injection of appropriate antibiotics: valuable for treatment of pyocyst in autosomal dominant polycystic kidney disease?
    Saedi D; Varedi P; Mahmoodi S; Varedi P
    Iran J Kidney Dis; 2009 Oct; 3(4):252. PubMed ID: 19841533
    [No Abstract]   [Full Text] [Related]  

  • 15. Introduction: new insights, treatments, and management strategies for ADPKD.
    Cowley BD
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1195-6. PubMed ID: 18322052
    [No Abstract]   [Full Text] [Related]  

  • 16. Autosomal dominant polycystic kidney disease: emerging concepts of pathogenesis and new treatments.
    Braun WE
    Cleve Clin J Med; 2009 Feb; 76(2):97-104. PubMed ID: 19188475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR inhibitors in ADPKD.
    Jamboti J
    Nephrology (Carlton); 2006 Aug; 11(4):377. PubMed ID: 16889582
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular pathogenesis of ADPKD and development of targeted therapeutic options.
    Ibraghimov-Beskrovnaya O
    Nephrol Dial Transplant; 2007 Dec; 22(12):3367-70. PubMed ID: 17971378
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting cyst initiation in ADPKD.
    Leuenroth SJ; Crews CM
    J Am Soc Nephrol; 2009 Jan; 20(1):1-3. PubMed ID: 19118147
    [No Abstract]   [Full Text] [Related]  

  • 20. Congenital hepatic fibrosis in a child with autosomal dominant polycystic kidney disease.
    Kanaheswari Y; Hamzaini AH; Wong SW
    Med J Malaysia; 2008 Aug; 63(3):251-3. PubMed ID: 19248702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.